Dendritic polyglycerol cores (5–100 kDa) bearing ≥30% alkyl-carboxylate groups irreversibly inactivate a broad range of viruses, including SARS-CoV-2 and HSV-2, with low cytotoxicity.

Detailed Explanation

The invention discloses dendritic polyglycerol (dPG) polymers synthesized by anionic ring-opening polymerization of glycidol, followed by allylation and thiol-ene click conjugation of alkyl-carboxylate chains (C5–C30 – COO-Na⁺). Functionalization degrees (DF ≥30%) are tunable via reagent ratios and reaction time. Optimized 10 kDa dPG cores with C13-COO–Na⁺ side chains (degree of functionalization ≥85–95%) show potent virucidal activity by wrapping virus particles, destroying viral particles irreversibly and preventing virus infection. In vitro assays demonstrate IC₅₀ ~79 µg/mL against HSV-2 and sub-micromolar efficacy against SARS-CoV-2, with minimal host toxicity. In vivo hamster studies confirm dose-dependent protection against SARS-CoV-2 and weight stabilization. Prototype formulations include topical creams, lip balms, and inhalable aerosols.

Key Innovation Features and Advantages

• Irreversible virucidal mechanism via alkyl-carboxylate functionalization, preventing viral rebound.
• Broad-spectrum efficacy against enveloped viruses, including SARS-CoV-2 and HSV-2.
• Low host cytotoxicity enabling safe therapeutic and disinfectant applications.

Use Cases

• Therapeutic sprays for treating respiratory infections such as COVID-19.
• Topical disinfectants for human and animal skin, hair, and living surfaces.
• Antiviral coatings for masks, textiles, medical devices, and high-touch surfaces.

Commercial Opportunities

• Development of inhaled and topical antiviral pharmaceuticals targeting emerging viruses.
• Consumer disinfectant products (gels, creams, sprays) with proven virucidal action.
  • Licensing of durable antiviral surface coatings for healthcare and public spaces.

Current Status

Lead candidate (dPG₁₀kDa-C₁₃-COO–Na⁺, DF ≥90%) has demonstrated strong in vitro and in vivo virucidal efficacy with established safety profiles. Prototype formulations are in preclinical development.